A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Diabetes Mellitus, Type 2

In brief

The study is testing UBT251 in participants with type 2 diabetes. The purpose of this clinical study is to find out if UBT251 is effective and safe for treating participants with type 2 diabetes. Participants will either get UBT251, UBT251 placebo, semaglutide, or semaglutide placebo. Which treatment participants get is decided by chance. UBT251 is the treatment being tested and is not yet available for doctors to prescribe, while semaglutide is a medicine used to treat type 2 diabetes that doctors can already prescribe.

Key facts

Study ID

NCT07668388

Run by

Novo Nordisk A/S

People needed

300

Starts

2026-06-22

Expected to finish

2027-11-15

Last updated by the study team

2026-07-14

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female (sex assigned at birth, inclusive of all gender identities).
• Age 18-75 years (both inclusive) at the time of signing the informed consent.
• Diagnosed with type 2 diabetes greater than or equal to (≥) 180 days before screening.
• Stable daily dose(s) ≥ 90 days before screening of the following antidiabetic drug(s) or combination regimen(s) at effective or maximum tolerated dose as judged by the investigator:
• metformin with or without sodium-glucose cotransporter-2 (SGLT2) inhibitor.
• HbA1c of 7.0-10.5 percent (%) (53-91 millimoles per mole (mmol/mol)) (both inclusive) as assessed by central laboratory at screening.
• Body mass index between 25.0 kg/m\^2 and 50.0 kg/m\^2 (both inclusive) at screening.

You may not qualify if…

• Treatment with any medication (prescription or over-the counter) or alternative remedies for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed.
• Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by an eye examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
• Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's questionnaire, question 8.

Where it is running

• Flourish Research — Birmingham, Alabama, United States (enrolling)
• Consano Clin Res-Shavano Park — Shavano Park, Texas, United States (enrolling)
• Ark Clinical Research — Fountain Valley, California, United States (enrolling)
• Catalina Research Institute, LLC — Montclair, California, United States (enrolling)
• Encore Medical Research LLC — Hollywood, Florida, United States (enrolling)
• Chrysalis Clinical Research — St. George, Utah, United States (enrolling)
• Encore Medical Research of Weston — Weston, Florida, United States (enrolling)
• Los Angeles Institute for Metabolic Research — Los Angeles, California, United States (enrolling)
• Cotton O'Neil Diabetes & Endocrinology — Topeka, Kansas, United States (enrolling)
• MD Medical Research — Oxon Hill, Maryland, United States (enrolling)
• Ark Clinical Research — Long Beach, California, United States (enrolling)
• KDCILM, LLC & Accellacare US, Inc. — Wilmington, North Carolina, United States (enrolling)
• South Broward Research LLC — Miramar, Florida, United States (enrolling)
• Preferred Primary Care Physicians, Inc. — Uniontown, Pennsylvania, United States (enrolling)
• Monroe Biomedical Research, LLC — North Charleston, South Carolina, United States (enrolling)
• LifeDoc Health — Memphis, Tennessee, United States (enrolling)
• IMA Clinical Research — Austin, Texas, United States (enrolling)
• Private Practice - Dr. Laila A. Hassan — Houston, Texas, United States (enrolling)
• Radiance Clinical Research — Lampasas, Texas, United States (enrolling)
• Quality Research Inc — San Antonio, Texas, United States (enrolling)
• Tekton Research Inc — San Antonio, Texas, United States (enrolling)
• Plains Clinical Research Center, LLC_Fargo — Fargo, North Dakota, United States
• The Vancouver Clinic — Vancouver, Washington, United States
• PharmQuest — Greensboro, North Carolina, United States
• Midwest Inst For Clin Res — Indianapolis, Indiana, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.